Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while State Street SPDR S&P Biotech ETF trades at $158.17. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $97.74 | $164.28 |
52-Week Low | $92.95 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
